KZIA Kazia Therapeutics Ltd

Novogen's Marshall Edwards Inc. Subsidiary Receives US$10.1 Million From Warrants Exercised SYDNEY, Australia, and STAMFORD, Conn., Dec. 4 /PRNewswire-FirstCall/ -- Novogen Limited announced today that its Marshall Edwards Inc. subsidiary (LSE-AIM: MSH) is in receipt of US$10.1 million from warrants exercised by Marshall Edwards' shareholders. Novogen is also listed in Australia (ASX:NRT), and manages its international research and development program using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). CONTACTS: United States Warren Lancaster (of Novogen) 203 327-1188 David Sheon (for Novogen) 202 518-6321 Australia Chris Naughton (of Novogen) +61-2-9878-0088 DATASOURCE: Novogen Limited CONTACT: In the United States: Warren Lancaster of Novogen Limited, +1-203-327-1188, or David Sheon, +1-202-518-6321, for Novogen Limited; in Australia: Chris Naughton of Novogen Limited, +61-2-9878-0088

Copyright